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Resumen
Los déficits neuropsicológicos se han des-
crito en las últimas dos décadas entre varios 
de los efectos secundarios de la quimioterapia 
adyuvante. Una revisión de la literatura mues-
tra especialmente que las mujeres con cáncer 
de mama después de la quimioterapia adyu-
vante sufren de este déficit. En este contexto 
se ha discutido la necesidad de programas de 
rehabilitación especiales para ayudar a las pa-
cientes a hacer frente a estas secuelas, pero 
hay sólo unos pocos intentos de programas de 
entrenamiento neuropsicológico para pacien-
tes con cáncer. En el presente estudio se com-
pararon dos tipos de intervenciones neuropsi-
cológicas en un centro de rehabilitación con 
un grupo control sin entrenamiento específico, 
con un total de 96 mujeres hospitalizadas rea-
lizando rehabilitación oncológica. La mayoría 
de los resultados de una batería neuropsicoló-
gica compresiva mejoraban significativamente 
durante la rehabilitación oncológica de las pa-
cientes en los tres grupos, mientras que no se 
pudo identificar un efecto de la intervención 
específica ni entre los dos grupos de interven-
ción, ni entre los grupos tratamiento y control. 
En cuanto a los exámenes de seguimiento se 
encontró que los déficits neuropsicológicos 
clínicamente relevantes seguían siendo evi-
Abstract
Among various side effects of adjuvant 
chemotherapy neuropsychological deficits 
have been described within the last two 
decades. A literature review shows that 
especially breast cancer women after adjuvant 
chemotherapy are suffering from these deficits. 
Against this background the need for special 
rehabilitation programms has been discussed 
to help the patients to cope with this sequelae, 
but there are only few attempts for special 
neuropsychological training programms for 
cancer patient. In the study presented we 
compared two types of neuropsychological 
interventions in a rehab setting against a 
control group with no specific training in a 
total of 96 female in-patients undergoing 
inpatient oncological rehabilitation. Most 
results of a comprehensive neuropsychological 
test battery improved significantly during 
the patients’ oncological rehabilitation in all 
three groups, whereas we could not identify 
a specific intervention effect neither between 
the two intervention groups nor between the 
treatment and control groups. In terms of the 
follow-up examination we found that clinically 
relevant neuropsychological deficits were still 
evident 6 months later in a small subgroup of 
patients. 
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dentes seis meses más tarde en un pequeño 
subgrupo de pacientes.
Palabras clave: Cáncer de mama, rehabi-
litación neuropsicológica, déficits cognitivos, 
efectos secundarios de la quimioterapia, efectos 
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observed an increase in cognitive deficits 
immediately after the conclusion of CHT, 
the patients’ test results one year later 
closely matched their scores at baseline. 
Still, most of the existing studies indicate 
that a subgroup of patients may present 
signs of cognitive deficits even long-term 
following adjuvant CHT. 
There is little specific information on 
potential risk factors in the literature so 
far. Scherwath et al.(9) assigned a particular 
role to methotrexate in the context of 
chemotherapy according to the CMF-
protocol (cyclophosphamide, methotrexate, 
5-fluorouracil); investigations on the effects 
of adjuvant anti-hormonal therapy (AHT) 
for breast cancer (without concurrent CHT) 
also indicate the possibility of cognitive 
deficits(15,16,17). Ahles & Saykin(11) discuss 
various theoretical models, yet there is no 
empirical proof justifying those approaches 
yet. 
For the most part there is increasing 
agreement that cognitive deficits should 
be regarded as a potential consequence 
of adjuvant therapy for breast cancer. 
The descriptions of long-term survivors 
also reveal that cognitive deficits can 
substantially impair functional capabilities 
in everyday life(18).
Although leading experts in the field have 
been recommending the development and 
evaluation of targeted neuropsychological 
therapy strategies(11,13,19), only few studies 
have been accomplished on the subject 
so far. Clinical neuropsychologists have 
been developed a broad spectrum of 
INTRODUCTION 
The aim of oncological rehabilitation 
is to identify physical, psychological, 
and social deficits, and to treat them via 
specific interventions(1). A number of papers 
have been published recently focussing 
on cognitive deficits following CHT for 
breast cancer(2-9). Yet they are difficult to 
compare due to major differences in study 
design, cohort make-up (i.e., age, CHT 
protocol, additional adjuvant therapies), 
the use of various neuropsychological test 
procedures, and the criteria for classifying 
neuropsychological deficits(10).
There is considerable agreement that 
cognitive deficits may be relevant, yet 
little consensus concerning the prevalence 
rates. However, there is general agreement 
that deficits are affecting the speed of 
information processing, attention, learning 
and memory, as well as “executive 
functions” (especially planning and effective 
performance of actions)(10,-13). As one 
important result among some studies the 
correlation between neuropsychological 
test results and the patients’ own appraisal 
of the deficits in their mental capability are 
low (3,5,14,5).
Most of the studies had a cross-section 
design; few were prospective in terms of 
how deficits change over the long term 
following the conclusion of CHT(4,7,8); only 
one trial had included tests administered 
prior to the start of CHT(7) and revealed 
cognitive deficits in about a third of the 
patients at that point. While Wefel et al.(7) 
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effective approaches for treating cognitive 
deficits as a consequence of neurological 
diseases and traumatic brain injury(20,21). 
Among those approaches there is a 
basic distinction between “restitutive” 
approaches such as functional training 
and “compensatory” strategies. The goal of 
functional training is to improve specific 
performance shortcomings directly, 
whereby compensatory strategies attempt 
to compensate on an everyday basis for 
the permanent loss of skills by capitalizing 
on still-intact cognitive functions, or via 
targeted behavioral strategies(20). While it 
is recognized that attentional skills can 
be improved by specific training, there 
is still no proof of specific functional 
improvement in memory, which is why 
the focus of neuropsychological therapy in 
that area lies in developing compensatory 
strategies(20,21). 
Ferguson et al.(22) were the first to 
publish encouraging data from a cognitive 
training program for breast cancer patients 
(Memory and Attention Adaption Training 
MAAT). The program concentrated on 
compensatory strategies for improving 
everyday skills and relaxation techniques 
within the framework of four individual 
meetings and three interspersed telephone 
consultations. They demonstrated positive 
effects on attention, memory, and executive 
functions in an initial evaluation of 29 
breast cancer patients whose CHT had 
been completed at least three years earlier. 
Moreover, they reported positive feedback 
from the patients regarding improvements 
in everyday mental skills. 
PATIENTS AND METHODS
Against this theoretical background, it 
was the aim of our study to implement 
a cognitive therapy approach in the 
rehabilitation of breast cancer patients 
following adjuvant CHT and to evaluate 
their effects. The study was conducted 
at the rehabilitation unit of the Tumor 
Biology Center, Freiburg Germany. The 
patients in our study were participating 
in an in-patient rehabilitation programm 
following oncological therapy immediately 
after the end of the adjuvant therapy 
for a regular stay of three weeks. The 
rehabilitation program includes medical 
diagnostics and treatment, physical and 
sport therapy, psychosocial treatment and 
other interventions (e.g. nutrition therapy, 
art therapy) in order to improve disease- 
and treatment-related deficits in functional 
status and quality of life(23). We developed 
two specific neuropsychological treatment 
strategies based on existing clinical 
neuropsychological approaches. The focus 
of both interventions was on improving 
functional attention and memory deficits 
which, according to the current literature, 
constitute the main potential problem 
areas for breast cancer patients. 
The Neuropsychological Training 
Group (NPT), with a maximum of 8 
participants, was led by a specialised 
occupational therapist who carried out a 
broad spectrum of activities concerned 
with attention and memory in everyday 
life. This type of training was focusing more 
real-life situation and was aimed to convey 
compensatory strategies that patients could 
apply directly in everyday activities. The 
training program has been collated in a 
manual comprising 15 units. 
The second intervention was an 
individualized, computer-based training (PC) 
under continuous therapeutic supervision. 
We used training software from different 
suppliers and assigned tasks addressing 
specific dimensions of attention and 
memory according to the parameters of our 
neuropsychological test battery (see Table 
1). The training was continuously adapted 
to suit the capabilities and training progress 
of the individual patient. Both interventions 
took part in four one-hour training sessions 
per week during their stay as in-patients. 
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The research questions were: 
1) Do the both intervention groups 
(NPT and PC) significantly improve the 
neuropsychological test parameters or/
and the self-appraisal scales (see Table 1) 
compared with the control group (CG) 
receiving no specific cognitive training.
2) Are there any differences for the both 
neuropsychological interventions in terms 
of the neuropsychological test parameter 
and the self-appraisal of cognitive 
functioning in everyday life. 
Measurements were taken upon 
admission to the rehabilitation unit (T1), at 
the end of rehabilitation (T2), and 6 months 
later on an out-patient basis (T3). Medical 
and sociodemographic data were acquired 
from the hospital’s documentation system.
All participants were recruited 
consecutively between September 2002 
and January 2004. They had undergone 
adjuvant CHT for stage I or II breast cancer. 
Exclusion criteria were: age over 64 
years, previous history of cancer, history 
of psychiatric or neurological symptoms 
likely to lead to cognitive deficits, current 
use of psychoactive medication, and 
insufficient command of the German 
language. The study was approved by the 
Ethics Committee of the medical faculty at 
the University of Freiburg. Patients were 
randomly assigned to the training groups. 
As randomization to non-treatment during 
the in-patient rehabilitation program was 
not feasible in terms of obtaining the 
patients’ acceptance, we recruited the 
CG over a “time-out” phase while we 
were offering no training. All participants 
provided written informed consent. Figure 
1 shows the study design.
To identify patients with cognitive deficits 
requiring specific treatment, we used three 
sub-tests of the computerized “Test Battery 
for Attentional Performance TAP”(24), which 
had proved in an earlier study to be 
particularly sensitive in detecting cognitive 
dysfunction in cancer patients(25). We chose 
five central measures (”Alertness”: reaction 
times with and without warning signal, 
“Reaction Change”: reaction time and 
errors, “Divided Attention”: sum of errors 
and omissions) and defined the criterion 
for training requirement according to earlier 
neuropsychological intervention studies(26) as 
results within the lowest quartile of the norm 
sample in at least two of the five parameters. 
Figure 1. Study design
PC: PC training; NPT: neuropsychological group therapy; CG: control group
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Table 1. Neuropsychological measures and questionnaires
Test Parameters Dimensions
TAP: Alertness RT with / without warning signal basic information processing speed
TAP: Reaction Change RT; false reactions mental flexibility
TAP: Divided Attention RT; sum of omissions and false reactions divided attention
TAP: Go/NoGo RT; false reactions selective attention
TAP: Sustained Attention omissions; false reactions sustained attention
RBMT: Story immediate and delayed reproduction verbal-semantic memory
WMS-R: Digit Span digit span forwards / backwards short-term memory; working memory
LGT-3 city map; objects figurative and spatial memory
Questionnaires Parameters
QLQ-C30: EORTC Quality of 
Life Questionnaire
Functional scales: Physical; Role; Cognitive; Emotional; Social; Global Health
Symptom scales: Fatigue; Nausea & Vomiting; Pain; Dyspnoea; Insomnia; Appetite Loss; 
Constipation; Diarrhoea; Financial Impact
MFI: Multidimensional Fatigue 
Inventory Scales: General F.; Physical F.; Reduced Activity; Reduced Motivation; Mental F.
HADS: Hospital Anxiety and 
Depression Scale Scales: Anxiety; Depression
FEDA: Questionnaire of Self-
Perceived Deficits in Attention
Scales: Distractibility and Retardation in Mental Tasks; Fatigue and Retardation in 
Activities of Daily Living; Reduced Drive 
RT: mean reaction time; TAP: Testbatterie zur Aufmerksamkeitsprüfung (“Test Battery for Attentional Performance”) 
(Zimmermann & Fimm(28)); RBMT: Rivermead Behavioral Memory Test (Wilson et al.(29)); WMS: Wechsler Memory 
Scale-R (Wechsler(30)); LGT-3: Lern- und Gedächtnistest (“Learning and Memory-Test”) (Bäumler(31)); QLQ-C30: 
EORTC Quality of Life Questionnaire QLQ-C30 (Aaronson et al.(32)); MFI: Multidimensional Fatigue Inventory 
(Smets et al.(33)); HADS: Hospital Anxiety and Depression Scale (Herrmann et al.(34)); FEDA: Fragebogen erlebter 
Defizite der Aufmerksamkeit (“Questionnaire of Self-Perceived Deficits in Attention”) (Zimmermann et al.(24)); 
Sturm(27)).
Patients fulfilling our inclusion 
criterion were asked to participate in 
the study. All study participants took a 
battery of standardized and validated 
neuropsychological tests for attention 
and memory. Health-related quality of 
life, fatigue and emotional status were 
evaluated using different questionnaires 
(see Table 1). Three questionnaire subscales 
(EORTC “Cognitive Functioning“; MFI 
“Mental Fatigue“; FEDA “Distractibility and 
Retardation in Mental Tasks“) specifically 
measured the patients’ self-appraisals of 
their everyday cognitive performance. 
The EORTC scale consists of two items 
that very generally address the degree of 
deficit in attention and memory in everyday 
life, with four possible answers ranging 
from “not at all” to “very”. The MFI scale, 
however, has four items concentrating 
exclusively on attention, with scores ranging 
between 1 and 5. We also administered the 
FEDA(24,26) to specifically evaluate attention 
deficits – it is a normed testing instrument 
used primarily in German-speaking 
Europe in neurological rehabilitation. The 
“Distractibility and Retardation in Mental 
Tasks” scale contains 11 items addressing 
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attention problems in concrete everyday 
situations; the five possible responses range 
from “very often” to “never”. Since the 
correlations between neuropsychological 
functional level, self-appraisal and potential 
moderating variables are not the main 
focus of this paper, the questionnaires are 
presented in their entirety only for purposes 
of completeness. We are working on a 
manuscript addressing that specific topic.
The Statistical Package for Social 
Sciences (SPSS; Windows 12.0 software) 
was used for statistical analyses. As 
statistical procedure differences were 
tested using the χ2-test for contingency 
and the Student’s t-test. We used Pearson’s 
r as correlation coefficient for normally 
distributed and Spearman’s rho for not 
normally-distributed variables. Intervention 
effects were analyzed in a mixed model by 
means of multivariate analysis of variance 
(MANOVA). We adjusted the α-level for 
multiple testing according to Bonferroni 
from 0.05 to 0.0026.
A total of 335 women with breast 
cancer fulfilling our inclusion criteria 
were admitted as in-patients during the 
recruitment period (from September 2002 
to January 2004). Based on the criteria 
for eligibility and after drop-outs due to 
various reasons we were able to include 
96 patients with complete data at T1 and 
T2. The reasons for drop outs were lack 
of interest in the training program or in 
the test examinations. Only few patients 
dropped out of the study due to interim 
relapse of disease and discharge from 
rehabilitation. N=90 patients could also 
be assessed at the third measurement 
point. Reasons for drop-outs between 
T2 and T3 were recurrent tumor activity 
(N = 3), lack of motivation (N = 1), and 
loss due to organizational factors (N = 2). 
The distribution on the three intervention 
groups was as follows (numbers of patients 
also assessed at T3 in brackets): NPT: N = 
33(33); PC: N = 34(32); CG: N = 29(25).
Table 2. Sociodemographical and medical data
n %
Age Professional Training
Mean (SD) 49.19 (7.71) Apprenticeship 54 56.3%
Range 32-64 Polytechnic 19 19.8%
University 16 16.7%
Other 4 4.2%
None 3 3.1%
Time since first diagnosis Chemotherapy
Mean (SD) 9.01 (3.39) CMF 13 13.5%
Range 3 - 24 CMF + Anthracyclines 7 7.3%
Anthracyclines 47 49.0%
Anthracyclines + Taxanes 29 30.2%
Time since last treatment
Mean (SD) 2.06 (2.78) Antihormonal Therapy 68 70.8%
Range 0 - 15 Radiotherapy 86 89.6%
CMF: cyclophosphamide, methotrexate, 5-fluorouracil; Anthracyclines: epirubicin or doxorubicin (in combina-
tion with cyclophosphamide); Taxanes: docetaxel or paclitaxel
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RESULTS
Description of the sample
The average age in our sample was 
49.19 (with a standard deviation [SD] 
of 7.71) years (Table 2). The level of 
education and professional training was 
above average: 16.7% (N = 16) of the 
sample had a university degree; only 3.1% 
(N = 3) were not professionally trained. 
The mean time since first diagnosis was 
9.01 (3.39) months; time since conclusion 
of therapy (excepting AHT) was on average 
2.06 (2.78) months. The CHT protocols our 
patients received reflect current clinical 
standards in treating breast cancer; the 
use of anthracyclines (docetaxel or 
paclitaxel) dominates. The vast majority 
of our patients underwent post-operative 
localized adjuvant radiation, and 70.8% 
(N = 68) were on AHT. 
Neuropsychological test results at T1
We selected 16 neuropsychological test 
scores for statistical analyses. Data at T1 are 
presented with T-values as benchmarks as 
far as possible. Exact T-values are missing 
for the TAP error indices (false reactions; 
omissions) and RBMT “Story”. Only 
percent rank norms are available for WMS 
“Digit Span”. To assess the frequency of 
clinically relevant deficits in the different 
Table 3. Neuropsychological test results at T1 (n = 96)
Test RS SD (RS) T SD (T)
Deficits
N %
ALTO 289.47 55.13 40.73 7.21 14 14.6%
ALPH 274.95 52.28 40.81 7.08 15 15.6%
RCRT 932.95 255.80 45.33 7.92 8 8.3%
RCFR 2.93 3.18 8 8.3%
DART 711.26 79.96 43.03 8.89 18 18.8%
DAER 4.15 3.42 8 8.3%
GNRT 416.42 56.98 49.69 7.06 3 3.1%
GNFR .75 1.15 1 1.0%
SAOM 11.88 7.37 47 49.0%
SAFR 7.17 8.93 19 19.8%
RBIM 9.48 3.18 30 31.1%
RBDL 8.45 3.31 33 34.4%
DSFW 8.07 1.88 54.93* 29.77* 4 4.2%
DSBW 7.58 1.92 60.26* 28.28* 3 3.1%
PLAN 14.64 4.63 43.53 8.17 15 15.6%
OBJC 9.60 2.49 50.47 9.06 3 3.1%
ALTO: Alertness tonic (without warning signal); ALPH: Alertness phasic (with warning signal); RCRT: Reaction 
Change, reaction time; RCFR: Reaction Change, false reactions; DART: Divided Attention, reaction time; DAER: 
Divided Attention, sum of false reactions and omissions; GNRT: Go/NoGo, reaction time; GNFR: Go/NoGo, 
false reactions; SAOM: Sustained Attention, omissions; SAFR: Sustained Attention, false reactions; RBIM: RBMT 
“Story” immediately; RBDL: RBMT “Story” delayed; DSFW: Digit Span forward; DSBW: Digit Span backward; 
PLAN: LGT-3 “City Plan”; OBJC: LGT-3 “Objects”; RS: raw score; SD: standard deviation; T: T-value * normed 
in percentiles.
378  Joachim Weis et al.
parameters, we applied a criterion used 
in other studies(7) and defined results of 
at least 1.5 SD below the mean of age-
adjusted norm data (corresponding to 
percent rank 6.7) as impaired. Since we 
noted no significant differences among 
the three groups, we have consolidated 
the results from the entire study group to 
facilitate clarity. Highest deficit rates were 
obtained from TAP “Working Memory 
and Sustained Attention“ and from RBMT 
“Story”, followed by both TAP “Alertness” 
parameters, reaction speed of TAP “Divided 
Attention” and the LGT-3-subtest “City 
Plan”. 87.5% (N = 84) of our study patients 
scored in at least one neuropsychological 
parameter in the impaired range, for 56.2% 
(N = 54) this was the case in two or more 
parameters. 
Multivariate analysis of the effects of 
training
Both intervention groups received 
on average 11.88 (SD = 2.42) training 
sessions per patient, with only a minimal 
and statistically not significant difference 
(p = .225) between PC training (12.24; SD 
= 2.56) and the NPT group (11.52; SD = 
2.24).
As the various parameters yielded very 
similar patterns, we illustrate the results 
from one attention and one memory test 
as well as one of the self-appraisal scales. 
In TAP “Tonic Alertness” (without 
warning signal) we observed a clear 
improvement in performance (reduced 
reaction times) in all 3 groups between 
T1 and T2. The time effect was significant 
in that interval, while we noted no 
interaction effect between time and group 
(and thus no specific intervention effect). 
The differences between the CG and two 
intervention groups were not significant due 
to considerably great intragroup variances 
(the error bars indicate the range of one 
SD around the mean). Between T2 and T3 
the curves flattened out quite obviously, 
we observed no time or interaction effect 
there either. 
In RBMT “Story” (delayed recall), 
we also observed a significant time 
effect between T1 and T2 (higher scores 
indicate more correctly reproduced text 
components); the interaction effect failed 
to meet the adjusted α-level, although both 
RBMT parameters (immediate and delayed 
recall) revealed a concordant tendency: 
the NPT group (which had the lowest 
baseline scores) improved much more than 
did the CG. While the CG’s performance 
continued to improve between T2 and 
T3, both intervention groups performed 
gradually worse at the last measurement 
Figure 2. Alertness without warning signal: reaction time
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Figure 3. RBMT Story: delayed recall
Figure 4. EORTC Cognitive Functioning
point. The three groups’ results at T3 were 
very similar overall.
The EORTC-scale “Cognitive Function-
ing“ showed general improvement between 
T1 and T2 (higher values indicate higher 
functional levels); variance analysis dem-
onstrated a significant time effect; the im-
provement trend became weaker between 
T2 and T3 and failed to meet the adjusted 
level of significance. Again we detected no 
statistically significant group effects or in-
teraction effects between time and group. 
Similar data were obtained from the other 
two self-appraisal scales (data not shown). 
In general, we observed significant 
improvement in performance between T1 
and T2 in 11 of the 16 neuropsychological 
parameters. There were no significant 
time effects in TAP “Go/NoGo” (reaction 
time), in either parameter of WMS “Digit 
Span“, nor in the two LGT subtests. None 
of the neuropsychological parameters 
revealed either a significant group or 
interaction effect at both time intervals. 
The improvement trend became weaker 
between T2 and T3; we detected a 
significant time effect in only 6 of the 16 
neuropsychological parameters. That was 
380  Joachim Weis et al.
the case in 4 of the 5 parameters that had 
shown no significant time effect between 
T1 and T2 (the exception: WMS “Digit 
Span forward”). 
6-month follow up at T3
Following our criterion of 1.5 SD 
under the mean of age-adjusted norm data 
at T3, we observed that 44.4% (N = 40) 
of our sample still displayed at least one 
deficitary result, 21.1% (N = 19) scored in 
two or more of the 16 neuropsychological 
parameters in the impaired range. We view 
the latter group as still cognitively impaired 
in a clinically-relevant sense. Although we 
identified an obvious general trend toward 
improvement in neuropsychological 
results, a subgroup of patients did remain 
that is still suffering from clinically-relevant 
cognitive deficits an average of one year 
after the end of cancer therapy. Again, 
TAP “Working Memory and Sustained 
Attention” and RBMT “Story” revealed 
the highest deficit rates. We attempted to 
identify predictors for neuropsychological 
deficits at T3 using various analyses 
(i.e., multiple regression analysis, cluster 
analysis). Medical and sociodemographic 
variables revealed no predictive value 
whatsoever; that was also the case for CHT 
according to CMF-protocol and adjuvant 
AHT (which had proven to be predictors 
for cognitive deficits at T1). The only 
significant parameter was the degree of 
neuropsychological deficits at T1, that is, 
the poorer a patient’s performance was at 
baseline, the higher the risk that she would 
be classified as having deficits at T3. 
We used reference data from the 
German general population for the 
EORTC-scale “Cognitive Functioning” for 
comparison with our sample. By applying 
the same criterion of 1.5 SD under the 
mean of age-adjusted norm data, we found 
that about 36% (N = 32) of our patients 
judged their everyday cognitive abilities to 
be below average.
Feedback from the training groups
We asked the patients at T2 for their 
opinion on the interventions. Table 5 
illustrates how helpful they found the 
information we had provided on cognitive 
deficits after CHT and the personal 
counselling they had received concerning 
their test results. We also asked them at 
T2 and T3 how useful they found the 
training to have been. The feedback was 
overwhelmingly positive - the vast majority 
(92.3%) judged the information to be 
“fairly” or “very helpful”, only 7.7% found 
it not so. We received the same positive 
feedback (93.8% “fairly helpful” or “very 
helpful”) on the test-results counselling, 
which only 6.2% found not particularly 
helpful. Most found the training helpful; 
that appraisal was considerably better at 
T3 than that made immediately at the end 
Table 4. Training Feedback (participants NPT/PC: N = 67 [T2] / 65 [T3])
Question -- - + ++
Information* 1 1.5% 4 6.2% 32 49.2% 28 43.1%
Personal counselling* - - 4 6.2% 23 35.4% 38 58.5%
Usefulness of training T2** 2 3.0% 10 14.9% 37 55.2% 18 26.9%
Usefulness of training T3** - - 2 3.1% 21 32.3% 42 64.6%
* -- “not helpful at all“; - “not particularly helpful“; + “fairly helpful“; ++ “very helpful” 
** -- “minimal“; - “quite low“; + “rather useful“; ++ “very useful“
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of the training program. While 26.9% of 
the patients found the training groups to be 
“very helpful” at T2, 64.6% did so at T3; the 
low scores (usefulness rated as quite “low” 
or “minimal”) fell from 17.9% at T1 to 3.1% 
at T3. There were no differences in this 
regard between the 2 intervention groups 
(data not shown). We believe these results 
and our patients’ impressive motivation 
to clearly illustrate the importance of this 
issue and the subjective usefulness of such 
interventions for breast cancer patients 
after adjuvant CHT. 
DISCUSSION
Although neurocognitive deficits 
after adjuvant chemotherapy have been 
described and investigated in many 
studies, there is a lack of knowledge in 
specific neuropsychological training 
programms in cancer rehabilitation. 
Therefore this is one of the first studies 
to systematically investigate the effects of 
specific neuropsychological rehabilitation 
strategies in breast cancer patients shortly 
after adjuvant therapy has been finished. 
Based on a randomized trial we aimed 
also to evaluate the feasibility of such a 
program in the context of in-patient cancer 
rehabilitation.
According to our criteria of 
neuropsychological impairment, we 
observed that 47.1% of the patients presented 
signs of possible cognitive deficits and the 
need for training. In line with the research 
literature our differentiated analyses of the 
neuropsychological test results revealed 
deficits especially in sustained attention, 
verbal-semantic memory, alertness (basic 
information processing speed), and divided 
attention; 87.5% of our study participants 
presented signs of clinically-relevant 
deficits in at least 1 of the 16 parameters we 
examined, and 56.2% did so in 2 or more. 
We observed significant improvement 
in performance in most of the 
neuropsychological parameters during 
in-patient rehabilitation in all three study 
groups. Since the control group (without 
specific training) improved in the same 
manner as the PC and NPT training groups, 
we could not demonstrate any specific 
intervention effects.
There may be several factors leading 
to this general improvement trend. First of 
all, there may be an overall spontaneous 
remission starting soon after the end 
of adjuvant therapy – in terms of both 
cognitive performance and physical 
condition (we also observed solid 
physical improvement during in-patient 
rehabilitation; symptomatic complaints 
such as fatigue were considerably 
reduced). Furthermore, there may be 
an unspecific effect of the in-patient 
rehabilitation programm itself on cognitive 
skills, as it includes manifold physical, 
intellectual, and emotional stimulation. 
Finally, longitudinal neuropsychological 
investigations requiring the same or very 
similar tasks of the patients always reflect 
the “danger”of practice effects being 
behind demonstrations of improvement.
To monitor any “unspecific effects” of 
in-patient rehabilitation, one would have 
to include a control group of patients not 
receiving such rehabilitation. Identifying 
training effects within the context of 
repeated neuropsychological tests is a 
complex problem – besides choosing 
instruments less susceptible to such effects 
(i.e., by using tests with parallel versions 
of equal difficulty), it is worth considering 
an additional preceding baseline testing as 
well. The intervention phase would not start 
until the second test, thus minimizing most 
of the practice effects, which are generally 
most pronounced between the first and 
second testing. Another alternative would 
be to include a healthy control group of 
similar age and education. The recently-
established „International Cognition and 
Cancer Task Force“ is working on setting up 
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guidelines so that future research activities 
can be better coordinated and their results 
more readily compared(35) .
Another possible explanation for our 
having failed to detect any significant 
intervention effects has to do with our 
inclusion criterion, which included patients 
presenting minor signs of neurocognitive 
deficits. Our cohort may well have included 
women whose capabilities were not at all 
or were only minimally impaired by CHT 
- meaning they would fail to demonstrate 
any substantial improvement after training. 
In the period following in-
patient rehabilitation, for the most 
neuropsychological parameters the 
improvement curves clearly flattened out. 
In that case, one must remember that 
that interval encompassed six months 
and lasted thus much longer than the in-
patient rehabilitation. In a few parameters, 
especially the more complex memory 
tasks, we did not observe significant 
improvement until the T2-T3 interval. 
Perhaps these skills improve more slowly 
than “basic“ attentional functions. The 
examination of improvement in various 
neuropsychological parameters over time 
would be an ideal subject for future 
investigations. 
We did observe a strong general 
trend toward improvement in the 
neuropsychological test scores, yet our data 
also reveal a subgroup of patients showing 
clinically-relevant cognitive deficits about 
one year after CHT (21.2% in 2 or more 
neuropsychological parameters). The 
degree of neuropsychological impairment 
at T1 (that is, the number of deficitary 
test scores) was the key predictor for 
cognitive status at T3. Our data indicate 
the possibility of persistent deficits in 
a subgroup of breast cancer patients 
after adjuvant CHT. These patients need 
differentiated and empirically evaluated 
cognitive rehabilitation strategies. We 
propose, in light of our present knowledge, 
an integrated and individualzed concept 
to that end - one combining functional 
training to improve attention and 
memory, the development of everyday 
compensatory strategies, and behavioural 
therapeutic approaches in dealing with 
any residual deficits. At the present time 
individual clinical case studies (Cicerone 
et al., 2000) are a reasonable alternative 
to control group study designs when the 
empiric examination of such interventions 
is being considered.
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